Cantor Fitzgerald Reiterates Neutral on Bluebird Bio
Bluebird Bio Analyst Ratings
bluebird bio | 10-Q: Q1 2024 Earnings Report
Express News | Bluebird bio Inc -Restatement Had No Impact on Company's Cash Position or Revenue
Bluebird Bio Announces Completion Of Its Restatement And Filing Of Its 2023 Form 10-K And Q1 2024 Form 10-Q >BLUE
bluebird bio | 10-K: FY2023 Annual Report
California Launches $500 Million Initiative for Zero-Emission School Buses -- OPIS
FDA Will Not Meet Ahead of Bluebird Bio's Sickle Cell Disease Gene Therapy PDUFA Date
Bluebird Bio Announces September Investor Events
Bluebird Bio Works to Resolve Financial Reporting Delays
Bluebird Bio Gets Nasdaq Noncompliance Notice
Bluebird Bio Recieves Receipt Of Delinquency Notice From Nasdaq; The Notices Have No Immediate Effect On The Listing Or Trading Of The Company's Common Stock On The Nasdaq.
Express News | Bluebird bio Announces Receipt of Expected Notices From Nasdaq
J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating
J.P. Morgan analyst Eric Joseph maintains $bluebird bio(BLUE.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 50.8% and a total average return of 4.4% over the
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)
What 4 Analyst Ratings Have To Say About Bluebird Bio
Bluebird Bio Shares Are Trading Lower After JP Morgan Downgraded the Stock From Overweight to Neutral and Multiple Firms Lowered Their Respective Price Targets on the Stock.
Bluebird Bio Is Maintained at Buy by B of A Securities
Bluebird Bio Price Target Cut to $3.00/Share From $4.00 by B of A Securities
RBC Capital Maintains Bluebird Bio(BLUE.US) With Hold Rating, Maintains Target Price $4
RBC Capital analyst Luca Issi maintains $bluebird bio(BLUE.US)$ with a hold rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 23.6% and a